Skip to content
PaperFren

Neurocognitive aging

Does brain tau protein affect object memory in older adults?

Berron D, Cardenas-Blanco A, Bittner D, et al. · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019

Open access · cc by · source: Europe PMC

Elevated levels of tau protein in the brain fluid of healthy older adults are linked to overactivity in the hippocampus and worse memory for distinguishing highly similar objects.

Study at a glance

Design
Other — Observational CSF biomarker–fMRI association study; no assigned exposure
N
N=21 · 21 cognitively unimpaired older adults analysed after spinal tap and mnemonic discrimination fMRI
Population
Cognitively unimpaired older adults
Outcome
Object mnemonic discrimination and hippocampal activation vs CSF tau

Structured fields used in claim comparison tables when every cited study has a complete layer.

Key findings

The researchers found that higher levels of tau proteins in the spinal fluid were associated with poorer performance in distinguishing similar objects, showing a negative correlation of -0.641. Higher tau levels were also linked to overactivity in the right hippocampus during the memory task, with a positive correlation of 0.545. This increased hippocampal activity was itself negatively linked to object memory performance, showing a correlation of -0.486. Amyloid protein levels, however, showed no relationship with memory performance.

Methodology

To investigate how early Alzheimer's-related proteins affect memory systems, researchers studied 21 cognitively unimpaired older adults. The participants underwent spinal taps to measure levels of tau and amyloid proteins in their cerebrospinal fluid. They also completed a memory test during functional MRI scanning, which involved 224 object and scene trials where they had to distinguish exact repeats from highly similar lure images.

Limitations

This study analyzed a very small sample size of only 21 participants, meaning the findings need replication in larger groups. Additionally, the cross-sectional, correlational design cannot prove that tau accumulation directly causes the brain overactivity or memory deficits. Furthermore, because spinal fluid biomarkers reflect overall brain levels rather than specific regional anatomy, the study cannot definitively pinpoint exactly where in the brain the tau protein is clustering.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • Blood GFAP and NfL associate with higher later dementia risk years before diagnosis.

    In UK Biobank adults with baseline plasma measures, higher GFAP and NfL associated with roughly doubled hazards of incident all-cause dementia over ~13 years, with elevations detectable up to about 15 years before diagnosis and incremental prediction beyond demographic risk scores.

    Scope note — different compartment — CSF tau + fMRI, not plasma GFAP/NfL

    Limits the claim's scope: a different population, assay, or outcome.

  • A VR navigation task can separate biomarker-positive MCI from controls.

    An entorhinal-cortex–based virtual navigation task produced larger path errors in MCI than controls, with biomarker-positive MCI performing worse than biomarker-negative MCI—linking a behavioural assay to CSF Alzheimer’s markers.

    Scope note — different behavioural assay — object mnemonic discrimination, not VR path error

    Limits the claim's scope: a different population, assay, or outcome.

  • Higher CSF tau can track early object-memory and hippocampal activity changes.

    In cognitively unimpaired older adults, higher CSF tau correlated with worse object mnemonic discrimination and greater right hippocampal task fMRI activity—evidence that a fluid marker can track early functional change before a dementia diagnosis.

    Evidence for the claim as stated.

  • VR navigation separates biomarker-defined MCI behaviourally; CSF tau in unimpaired adults tracks hippocampal hyperactivity and object memory. Shared theme: early Alzheimer’s biology can show up before frank dementia—different tasks, samples, and endpoints.

    Evidence for the claim as stated.

  • Higher plasma NfL associates with higher later dementia risk in UK Biobank adults.

    In UK Biobank adults with baseline plasma measures, higher NfL (and GFAP) associated with roughly doubled hazards of incident all-cause dementia over ~13 years, with protein elevations detectable up to about 15 years before diagnosis and useful incremental prediction alongside demographic risk scores.

    Scope note — different assay and compartment — CSF tau, not plasma NfL

    Limits the claim's scope: a different population, assay, or outcome.

  • Higher CSF tau can track early memory and hippocampal activity changes before dementia.

    In cognitively unimpaired older adults, higher CSF tau correlated with worse object mnemonic discrimination and greater right hippocampal task fMRI activity—evidence that a fluid neurodegeneration marker can track early functional brain changes before a dementia diagnosis.

    Evidence for the claim as stated.

  • Plasma GFAP/NfL at biobank scale forecast registry dementia years later; CSF tau in a small imaging sample tracks hippocampal hyperactivity and object memory. They share the idea that fluid markers can flag neurodegeneration early, while answering different assay, sample, and outcome questions.

    Evidence for the claim as stated.

Open questions

Tensions this paper is part of

From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.

  • Scope difference — different assays, populations, or outcomes

    VR navigation separates biomarker-defined MCI behaviourally; CSF tau in unimpaired adults tracks hippocampal hyperactivity and object memory. Shared theme: early Alzheimer’s biology can show up before frank dementia—different tasks, samples, and endpoints.

  • Scope difference — different assays, populations, or outcomes

    Plasma GFAP/NfL at biobank scale forecast registry dementia years later; CSF tau in a small imaging sample tracks hippocampal hyperactivity and object memory. They share the idea that fluid markers can flag neurodegeneration early, while answering different assay, sample, and outcome questions.

    Also on this tension

Related papers in this topic

Same topic cluster — not a recommendation engine.